Okanagan Clinical Trials

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease7 trials
• Autism1 trial
• Depression1 trial

Phase

• Phase 36 trials
• Phase 23 trials

Status

• Active, not recruiting5 trials
• Completed2 trials
• Recruiting1 trial
• Suspended1 trial

Lead sponsor

• Hoffmann-La Roche3 trials
• Acumen Pharmaceuticals1 trial
• Alector Inc.1 trial
• AriBio Co., Ltd.1 trial
• COMPASS Pathways1 trial
• and 2 more

Running trials

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

  NCT06335173· Phase 2· Acumen Pharmaceuticals· Source

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· COMPASS Pathways· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· AriBio Co., Ltd.· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting

Closed trials

• Completed

  A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

  NCT04299464· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

  NCT04592874· Phase 2· Alector Inc.· Source